Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (NASDAQ: NTRA) is a diagnostic and research company in the medical laboratories industry, focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. The Natera news feed on Stock Titan highlights company announcements, clinical data readouts, collaborations, and financial updates that reflect how its testing platforms are used in practice and research.
Recent news has featured advances in molecular residual disease (MRD) testing with Signatera, including new multi-modal AI models that integrate longitudinal circulating tumor DNA, clinical data, digital pathology, and tumor sequencing to refine recurrence risk assessment and outcomes prediction. Natera also reports on large clinical studies and trial analyses in colorectal cancer and breast cancer, where Signatera is used to evaluate MRD, predict treatment response, and support risk stratification.
In women’s health, news items include the launch and validation of Fetal Focus, a single-gene non-invasive prenatal test that uses cell-free DNA from maternal blood to assess inherited conditions when partner testing is not available, as well as updates related to the broader prenatal and carrier screening portfolio. Organ health news may cover the use of Natera’s Prospera test in transplant rejection assessment and related research.
Investors and clinicians can also follow Natera’s announcements about AI collaborations, such as its work with NVIDIA to scale multimodal AI foundation models, and corporate updates including preliminary financial results and participation in healthcare conferences. For those tracking NTRA, this news page provides a centralized view of developments across oncology, women’s health, organ health, and AI-enabled diagnostics.
Natera (NASDAQ: NTRA) published a prospective study in Clinical Cancer Research showing Signatera MRD testing identified older women with early-stage ER+/HER2- breast cancer who could forgo surgery and remain progression-free while receiving primary endocrine therapy (pET).
Key findings: 68% baseline MRD-negative (0 progressions), 100% baseline negative predictive value, and 100% longitudinal sensitivity for progression detection; 43 patients enrolled, monitored every 3–6 months.
Natera (NASDAQ: NTRA) reported two peer‑reviewed studies showing clinical utility of Signatera, its personalized ctDNA assay, in anal squamous cell carcinoma (ASCC) and locally advanced rectal cancer (LARC).
In ASCC (n=84), Signatera‑negative or cleared patients had 100% one‑year OS and PFS, while post‑CRT ctDNA‑positive patients showed worse one‑year outcomes (63% OS; 44% PFS). In LARC (n=220), Signatera positivity after neoadjuvant therapy predicted higher regrowth risk (HR 4.62; p=0.003) and much higher relapse (88.0% vs 11.5%; p<0.0001).
MyOme and Natera (NASDAQ: NTRA) launched the Zenith™ portfolio, a premium exome and genome testing solution integrating MyOme's long-read methylation analysis with Natera's clinical network.
Methylation analysis will be automatically added to all eligible rare disease exome and genome orders starting early Q2 2026, initially as targeted confirmation for select conditions.
Natera (NASDAQ: NTRA) announced the commercial launch of Zenith genomics, a next-generation whole genome sequencing assay for rare disease diagnosis, on March 12, 2026.
Zenith uses a whole-genome backbone plus long-read sequencing confirmation to improve detection of hard-to-detect features like tandem repeat expansions. The launch follows an exclusive partnership with MyOme and leverages Natera's EMR integration, clinical support, and nationwide commercial footprint. The company cites 30 million Americans affected by rare disease, typical diagnostic journeys of 4–7 years, and a 2019 U.S. economic burden estimate of $997 billion to frame market need. Natera is presenting Zenith at the 2026 ACMG meeting to showcase platform performance and real-world utilization.
Natera (NASDAQ: NTRA) will present 11 abstracts at ASCO GU (Feb 26-28, 2026) showing Signatera MRD's potential across genitourinary cancers.
Key findings include 73–77% ctDNA clearance in MIBC, Signatera-negativity linked to high two-year bladder-intact EFS (88.6% and 91%), and complementary utDNA+ctDNA perioperative stratification.
Natera (NASDAQ: NTRA) reported strong fourth-quarter and full-year 2025 results with significant revenue, margin, volume, and cash improvements.
Total revenue was $665.5M in Q4 2025 (+39.8% YoY) and $2,306.1M for FY2025 (+35.9%). Gross margin improved to 66.9% in Q4 and 64.7% for FY2025. Tests processed rose ~15.0% for the year, and the company achieved a positive cash inflow of $107.6M for FY2025.
Natera (NASDAQ: NTRA) reported Phase 2 SINERGY results in recurrent/metastatic head and neck squamous cell carcinoma showing a 63% objective response rate (17/27) and ctDNA-guided de-escalation in 74% of patients (20/27). Median chemotherapy exposure fell to 2 cycles versus a 6-cycle standard, with grade ≥3 toxicity at 48.1%. Data were presented as an oral plenary at the 2026 MHNCS.
Natera (NASDAQ: NTRA) will release its fourth quarter and full year 2025 results after market close on February 26, 2026. A conference call and webcast will follow at 1:30 p.m. PT / 4:30 p.m. ET.
Investors can join via dial-in (Conference ID 7684785) or the webcast link; a replay will be available at the company investor site.
Natera (NASDAQ: NTRA) launched EDEN, a large U.S. prospective study to evaluate a non-invasive prenatal screening test for early risk assessment of preeclampsia and other adverse pregnancy outcomes. The study plans to enroll up to 7,500 participants at 9–15 weeks' gestation and combines cfDNA, additional analytes, and clinical data.
EDEN builds on prior research linking cfDNA markers to pregnancy complications and aims to detect earlier-onset and more severe preeclampsia with routine prenatal data.
Natera (NASDAQ: NTRA) submitted a premarket approval (PMA) to the U.S. FDA for Signatera CDx to detect molecular residual disease (MRD) in muscle-invasive bladder cancer (MIBC) patients who may benefit from atezolizumab.
The PMA is supported by randomized, double-blind phase 3 IMvigor011 data showing Signatera-guided therapy improved disease-free and overall survival for Signatera-positive patients, while Signatera-negative patients had low recurrence risk without adjuvant immunotherapy. Results were presented at ESMO and published in The New England Journal of Medicine.